Valeant enters commercialization agreement with Spear for anti-wrinkle cream
ALISO VIEJO, Calif. Valeant Pharmaceuticals International has obtained the right to commercialize an anti-wrinkle cream under a deal with Spear Pharmaceuticals, Valeant announced Monday.
Valeant plans to deploy its sales force nationwide to promote Refissa (tretinoin) to dermatologists. In exchange, it will pay Spear $12 million upfront and share profits on the drug. Refissa had sales of around $5 million in 2009.
“Our strategy is to offer a diverse portfolio of innovative, high-quality products to dermatologists and their patients who want healthier-looking skin,” Valeant chairman and CEO J. Michael Pearson said.